Dual-Purpose pill: roxadustat may fight both anemia and muscle wasting in dialysis

NCT ID NCT07162090

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tests whether roxadustat, a drug currently used to treat anemia in kidney disease, can also improve sarcopenia (muscle loss) in patients on hemodialysis. Sixty adults with end-stage kidney disease and anemia will receive either roxadustat or standard erythropoietin. Researchers will measure changes in muscle strength, size, and walking speed over time.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Roxadustat (a pill that helps the body produce more red blood cells and may affect muscle health)
What this could lead to
If it works, roxadustat could offer a way to treat both anemia and muscle loss in dialysis patients with a single pill.
What could go wrong
This is a small, early-phase study with only 60 participants, so results may not apply to everyone. Roxadustat is already used for anemia, but its effect on muscle loss is unproven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANEMIA ASSOCIATED WITH CHRONIC KIDNEY DISEASE (CKD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

More trials for these conditions

Other studies related to the condition(s) this trial covers.